Multicenter comparative study to examine the efficacy of zoledronic acid in prostate cancer with bone metastasis at different hormone sensitivity status.

Multicenter comparative study to examine the efficacy of zoledronic acid in prostate cancer with bone metastasis at different hormone sensitivity status. - Multicenter comparative study to examine the efficacy of zoledronic acid in prostate cancer with bone metastasis at different hormone sensitivity status.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002792

Enrollment

200

Registered

2009-11-26

Start date

2007-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer with bone metastasis

Interventions

Hormon sensitive during zoledronic acid therapy Hormon refractory after zoledronic acid therapy Hormon refractory before zoledronic acid therapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients of prostate cancer with bone metastasis

Exclusion criteria

Exclusion criteria: 1.History of hypersensitivity for zoledronic acid or other bisphosphonate 2.Renal dysfunction(serum creatinine more than 3.0mg/dL) 3.Active concomititant malignancy 4.Severe coexisting disease 5.Invasive dental treatment within 3 months 6.Other bisphosphonate therapy for injection within 6 months 7.Not suitable for this trial

Design outcomes

Primary

Measure	Time frame
Change of bone metastasis EOD grade	—

Secondary

Measure	Time frame
Change of SRE and BPI	—

Countries

Japan

Contacts

Public ContactTakatsugu Okegawa

Kyorin University Department of urology

0422-47-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026